ICBS to focus on pharmaceutical and environment...( NEW YORK MONTREAL and SAN DIEGO Aug. ...),Health

NEW YORK, MONTREAL, and SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ - ICBS Ltd., (OTCPK: ICBT), board of directors, announced that the company will focus its efforts on the pharmaceutical market through its subsidiary, Canadian Bio Med Systems Ltd., and the environmental market through its partnership with BioSpec Global Solutions Inc., of Quebec.

                       High Interest in a New Approach

"We feel that at this point, we should concentrate on the most promising investments and that is with Canadian Bio Med Systems and BioSpec Global Solutions. We have therefore decided to cease offering business consulting services through our subsidiary, Inter Canadian Business Services along with divesting our interest in Ramapo Valley Brewery" said Dr. George Tsoukas, Chairman.

ICBS has positioned itself with 51% ownership in Canadian Bio Med Systems and 25% interest in BioSpec Global Solutions.

These companies have entered a multi billion dollar market place in recession proof industries.

ICBS will continue to acquire undervalued opportunities in these selective high-growth industries to create value for our shareholders and target partners by combining expertise in both the product and capital markets. Taking interest in companies to align with their long-term interest and help build enduring value for our investors.

Canadian Bio Med Systems, has acquired the licensing rights to two new potentially revolutionary drugs in the billion dollar ophthalmic arena. The drug for the treatment of Glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world, and Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for p
'/>"/>